Existing kinase drugs can prevent SARS-CoV-2 from hijacking cells


An international team of researchers has analyzed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins in its target cells.

The research, published in the journal Cell, shows how the virus shifts the cell’s activity to promote its own replication and to infect nearby cells.

The scientists also identified seven clinically approved drugs that could disrupt these mechanisms, and recommend that these drugs be immediately tested in clinical trials.

The collaboration included researchers at EMBL’s European Bioinformatics Institute (EMBL-EBI), the Quantitative Biosciences Institute’s Coronavirus Research Group in the School of Pharmacy at University of California San Francisco (UCSF), the Howard Hughes Medical Institute, the Institut Pasteur, and the Excellence Cluster CIBSS of the University of Freiburg.

Viruses are unable to replicate and spread on their own: they need an organism – their host – to carry, replicate, and transmit them to further hosts.

To facilitate this process, viruses need to take control of their host cell’s machinery and manipulate it to produce new viral particles. Sometimes, this hijacking interferes with the activity of the host’s enzymes and other proteins.

Once a protein is produced, enzymes can change its activity by making chemical modifications to its structure. For example, phosphorylation – the addition of a phosphoryl group to a protein by a type of enzyme called a kinase – plays a pivotal role in the regulation of many cell processes, including cell-to-cell communication, cell growth, and cell death.

By altering phosphorylation patterns in the host’s proteins, a virus can potentially promote its own transmission to other cells and, eventually, other hosts.

The scientists used mass spectrometry, a tool to analyze the properties of a sample by measuring the mass of its molecules and molecular fragments, to evaluate all host and viral proteins that showed changes in phosphorylation after SARS-CoV-2 infection.

They found that 12% of the host proteins that interact with the virus were modified. The researchers also identified the kinases that are most likely to regulate these modifications. Kinases are potential targets for drugs to stop the activity of the virus and treat COVID-19.

The extraordinary behavior of infected cells

“The virus prevents human cells from dividing, maintaining them at a particular point in the cell cycle. This provides the virus with a relatively stable and adequate environment to keep replicating,” explains Pedro Beltrao, Group Leader at EMBL-EBI.

SARS-CoV-2 not only impacts cell division, but also cell shape. One of the key findings from the study is that infected cells exhibit long, branched, arm-like extensions, or filopodia. These structures may help the virus reach nearby cells in the body and advance the infection, but further study is warranted.

“The distinct visualization of the extensive branching of the filopodia once again elucidates how understanding the biology of virus-host interaction can illuminate possible points of intervention in the disease,” says Nevan Krogan, Director of the Quantitative Biosciences Institute at UCSF and Senior Investigator at Gladstone Institutes.

Old drugs, new treatments

“Kinases possess certain structural features that make them good drug targets. Drugs have already been developed to target some of the kinases we identified, so we urge clinical researchers to test the antiviral effects of these drugs in their trials,” says Beltrao.

In some patients, COVID-19 causes an overreaction of the immune system, leading to inflammation. An ideal treatment would relieve these exaggerated inflammatory symptoms while stopping the replication of the virus. Existing drugs targeting the activity of kinases may be the solution to both problems.

The researchers identified dozens of drugs approved by the Food and Drug Administration (FDA) or ongoing clinical trials that target the kinases of interest. Seven of these compounds, primarily anticancer and inflammatory disease compounds, demonstrated potent antiviral activity in laboratory experiments.

“Our data-driven approach for drug discovery has identified a new set of drugs that have great potential to fight COVID-19, either by themselves or in combination with other drugs, and we are excited to see if they will help end this pandemic,” says Krogan.

“We expect to build upon this work by testing many other kinase inhibitors while identifying both the underlying pathways and additional potential therapeutics that may intervene in COVID-19 effectively,” says Kevan Shokat, Professor in the Department of Cellular and Molecular Pharmacology at UCSF.

Inhibition of SARS-CoV-2 fusion/entry.Similarly to SARS-CoV, SARS-CoV-2 uses spike (S) protein to gain entry into host cells (8).

It was shown that the S protein on the surface of SARS-CoV-2 cell bound the entry receptor angiotensin-converting enzyme 2 (ACE2) on infected cells (9). SARS-CoV-2 was predicted to recognize human ACE2 more efficiently than SARS-CoV (10).

Thus, targeting the interactions between ACE2 and S protein may be a potential approach. Specifically, a receptor binding domain (RBD) within the S protein is the critical target for neutralizing antibodies. Since SARS-CoV-2 S protein displayed high homology to that of SARS-CoV, the available neutralizing antibody of SARS-CoV CR3022 was found to bind potently with SARS-CoV-2 RBD (4).

Nevertheless, Zheng and Song recently reported that more than 85% of the RBD antibody epitopes in SARS-CoV-2 showed remarkable alterations compared with SARS-CoV, indicating the necessity to develop new monoclonal antibodies for SARS-CoV-2 (11). In addition, the rationale for the choice of the ACE2 receptor as a specific target has been reviewed elsewhere (12, 13).

Notably, an open-label, randomized, controlled, pilot clinical trial is in progress, further investigating the effect of recombinant human ACE2 (rhACE2; GSK2586881) in patients with severe COVID-19 (ClinicalTrials registration no. NCT04287686). It was suggested that S protein-derived cell entry depended on not only ACE2 but also on the host cellular serine protease TMPRSS2 (14).

Camostat mesylate, a clinically proven inhibitor of TMPRSS2, significantly reduced lung cell line infection with SARS-CoV-2 and could be considered for COVID-19 treatment (14). In addition, heptad repeat 1 (HR1) and heptad repeat 2 (HR2) on SARS-CoV-2 involved viral and cell membrane fusion (15). Xia et al. reported that HR2-derived peptides (HR2P) and EK1 (a modified OC43-HR2P peptide) exhibited effective fusion inhibitory activity toward SARS-CoV-2 and would act as fusion/entry inhibitors to treat SARS-CoV-2 infection. Further studies are warranted to substantiate these concepts.

Moreover, it was suggested that coronavirus entry also involved pH- and receptor-dependent endocytosis (16, 17). Targeting endocytosis may be another option for fighting SARS-CoV-2. AP-2-associated protein kinase 1 (AAK1) is a host kinase that regulates clathrin-mediated endocytosis (18). A group of approved drugs targeting AAK1 were searched out based on artificial intelligence (AI) technology (19).

Among them, the Janus kinase inhibitor baricitinib, an AAK1-binding drug, was expected to be a suitable candidate drug for COVID-19 because the standard treatment doses of baricitinib were sufficient to inhibit AAK1 (19).

Arbidol and chloroquine phosphate have been added to the list of potential treatment options in the NHC guideline for COVID-19 treatment (7). Arbidol was shown to inhibit multiple enveloped viruses by inhibiting virus entry/fusion of viral membranes with cellular membranes (20).

Chloroquine, a traditional antimalarial drug, was shown to be effective against SARS-CoV-2 infection in vitro (21). Several clinical trials are in progress to test the efficacy and safety of chloroquine phosphate against COVID-19 (22).

Results from more than 100 patients provided the first evidence that chloroquine phosphate was more effective in inhibiting the exacerbation of pneumonia than control treatment (22). Additionally, Yao et al. found that hydroxychloroquine (50% effective concentration [EC50] = 0.72 μM) was more potent with respect to inhibiting SARS-CoV-2 than chloroquine (EC50 = 5.47 μM) in vitro (23).

Most importantly, the molecular mechanism of chloroquine phosphate in the treatment of COVID-19 remains elusive. It has been reported that chloroquine could impair endosome-mediated viral entry or the late stages of viral replication (24). More efforts are needed to pin down the exact mechanism.

Disruption of SARS-CoV-2 replication.

Many antiviral agents have been developed against viral proteases, polymerases, MTases, and entry proteins. Clinical trials are currently in progress to test a number of antiviral drugs, such as remdesivir (ClinicalTrials registration no. NCT04252664 and NCT04257656), favipiravir (Chinese Clinical Trial registration no. ChiCTR2000029600 and ChiCTR2000029544), ASC09 (ChiCTR2000029603), lopinavir/ritonavir (ChiCTR2000029387, ChiCTR2000029468, and ChiCTR2000029539), and arbidol (ChiCTR2000029621). Martinez reported that the most promising antiviral for fighting SARS-CoV-2 was remdesivir (25).

Remdesivir is a monophosphoramidate prodrug of an adenosine analog. Its active form can incorporate into nascent viral RNA by the activity of RNA-dependent RNA polymerases (RdRps), which then causes RNA synthesis arrest (26).

Wang et al. demonstrated that remdesivir effectively inhibited SARS-CoV-2 in vitro (21). The clinical condition of the patient with the first case of COVID-19 confirmed in the United States improved following intravenous remdesivir administration (27). Similarly, favipiravir and ribavirin are monophosphoramidate prodrugs of guanine analogues and have been approved for treatment of infections by some other viruses (28).

However, their antiviral effect in patients with COVID-19 needs rigorous data to support their use. Lopinavir and ritonavir are protease inhibitors targeting the coronavirus main proteinase (3C-like protease; 3CLpro).

3CLpro is responsible for processing the polypeptide translation product from the genomic RNA into the protein components (29). High-throughput screening was also used to screen small-molecule drugs targeting the viral main protease in clinical drug libraries (30). Four molecules, including prulifloxacin, tegobuvir, bictegravir, and nelfinavir, showed reasonable binding conformations with the viral main protease (30).

Targeting the RNA genome of SARS-CoV-2 may be another approach. Nguyen et al. showed the application of the novel CRISPR/Cas13 RNA knockdown system in cleaving the SARS-CoV-2 RNA genome (31). This CRISPR/Cas13d system was composed of a Cas13d protein and guide RNA-containing spacer sequences specifically complementary to the virus RNA genome. It was suggested that the Cas13d effector could be delivered via an adeno-associated virus (AAV) to the lung infected with SARS-CoV-2 (31).

Suppression of excessive inflammatory response.

A coordinated cytokine response is essential for the host immune response. However, a dysregulated response leads to a hyperinflammatory condition in some patients infected with SARS-CoV-2. It was reported that patients in intensive care units (ICUs) had higher concentration of cytokines in plasma than non-ICU patients with COVID-19, suggesting that the cytokine storm was associated with disease severity (32).

Besides, higher percentages of granulocyte-macrophage colony-stimulating factor-positive (GM-CSF+) and interleukin-6-positive (IL-6+) CD4+ T cells were isolated from ICU patients infected with SARS-CoV-2 than from non-ICU patients (33).

In view of this, inhibition of excessive inflammatory response may represent an adjunct therapy for COVID-19. Nevertheless, the therapeutic use of corticosteroids, which has shown excellent pharmacological effects with respect to suppressing exuberant and dysfunctional systematic inflammation, is still controversial (25, 32).

The current NHC guideline emphasizes that the routine use of systematic corticosteroids is not recommended unless indicated for another reason. In line, there were no available data showing that patients benefited from corticosteroid treatment in SARS-CoV or Middle East respiratory syndrome coronavirus (MERS-CoV) infection, which might be attributable to the suppression of immune response against virus (34).

Notably, a recent retrospective study showed the potential benefits accruing from low-dose corticosteroid treatment in a subset of critically ill patients with SARS-CoV-2 (35). More studies are needed to find out how and when to use corticosteroids properly.

At the cellular level, Zhou et al. demonstrated that CD4+ T cells were rapidly activated to produce GM-CSF and other inflammatory cytokines after SARS-CoV-2 infection, which further induced CD14+ CD16+ monocyte activation with high levels of expression of interleukin 6 (IL-6) (33).

Thus, blocking GM-CSF or IL-6 receptor would potentially reduce immunopathology caused by SARS-CoV-2. In line, a multicenter, randomized, controlled clinical trial is under way to examine the efficacy and safety of tocilizumab (an IL-6 receptor-specific antibody) in patients with COVID-19 (Chinese Clinical Trial registration no. ChiCTR2000029765).

Moreover, Fu et al. mentioned possible mechanisms of SARS-CoV-2-mediated inflammatory responses in which the neutralizing antibodies triggered Fc receptor (FcR)-mediated inflammatory responses and acute lung injury (36). Various options to block FcR activation might reduce SARS-CoV-2-induced inflammatory responses (36).

Convalescent plasma treatment.

With infections for which there is no specific therapy available, therapy with convalescent plasma (CP) has been proposed as a principal treatment (37). The CP is obtained from a donor who has recovered from infection by developing humoral immunity against the SARS-CoV-2 (38). The protective and therapeutic benefit of CP was attributed to the possible source of specific antibodies of human origin (39).

However, evaluation of the efficacy of CP treatment is still difficult because of the lack of high-quality randomized clinical trials and of knowledge of the precise mechanism of action of plasma therapy.

According to the NHC guideline, the CP of recovered patients is mainly used for patients in rapid disease progression or in a severe or critical condition (40). Several clinical trials investigating the efficacy and safety of convalescent plasma transfusion in patients with COVID-19 are in progress (Chinese Clinical Trial registration no. ChiCTR2000030010, ChiCTR2000030179, and ChiCTR2000030381).


With the global spread of SARS-CoV-2, vaccination must be the most efficient and cost-effective means to prevent and control COVID-19 (41). Robust research efforts are under way to facilitate the development of vaccines against SARS-CoV-2. Specifically, the S protein of SARS-CoV-2 remains a key target for vaccine development.

Recently, Wrapp et al. reported and shared the cryo-electron microscopy (cryo-EM) structure of SARS-CoV-2 S trimer, which enabled additional protein engineering efforts and speeded up the process of vaccine development (42).

In addition, Lucchese searched the pentapeptides unique to SARS-CoV-2 by comparing the viral and the human proteomes and found that 107 human-foreign pentapeptides were embedded in S protein (43). Further, these S protein pentapeptides yielded 66 candidate epitopes for vaccine development (43).

Moreover, since there were few available immunological studies related to SARS-CoV-2, Ahmed et al. screened the SARS-CoV-derived epitopes due to its high level of genetic similarity with SARS-CoV-2 (44). A screened set of SARS-CoV-derived B cell and T cell epitopes that mapped identically to SARS-CoV-2 proteins were identified, which would help the initial phase of vaccine development (44).

More than 15 potential vaccine candidates for treatment of COVID-19 infection are being developed around the world, including inactivated vaccine, recombinant subunits vaccine, nucleic acid-based vaccine, adenoviral vector vaccine, recombinant influenza viral vector vaccine, etc. (45).

On 23 January 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced the finding on DNA, mRNA, and “molecular clamp” vaccine platforms (46). There was no existing literature on SARS-CoV-2 vaccine trials as of 13 March 2020. The safety of vaccine remains a top priority for vaccine development.

8.Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. 6 March 2020, posting date. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell doi:10.1016/j.cell.2020.02.058.
9.Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273. doi:10.1038/s41586-020-2012-7.
10.Wan Y, Shang J, Graham R, Baric RS, Li F. 29 January 2020, posting date. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol doi:10.1128/JVI.00127-20.Abstract/
11.Zheng M, Song L. 4 March 2020, posting date. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV. Cell Mol Immunol doi:10.1038/s41423-020-0385-z.
12.Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. 3 March 2020, posting date. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med doi:10.1007/s00134-020-05985-9.
13.Kruse RL. 2020. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res 9:72. doi:10.12688/f1000research.22211.1.
14.Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu N-H, Nitsche A, Müller MA, Drosten C, Pöhlmann S. 4 March 2020, posting date. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell doi:10.1016/j.cell.2020.02.052.
15.Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y, Ying T, Liu S, Shi Z, Jiang S, Lu L. 11 February 2020, posting date. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol doi:10.1038/s41423-020-0374-2.
16.Inoue Y, Tanaka N, Tanaka Y, Inoue S, Morita K, Zhuang M, Hattori T, Sugamura K. 2007. Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J Virol 81:8722–8729. doi:10.1128/JVI.00253-07.Abstract/
17.Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C. 2008. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res 18:290–301. doi:10.1038/cr.2008.15.
18.Neveu G, Ziv-Av A, Barouch-Bentov R, Berkerman E, Mulholland J, Einav S. 2015. AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets. J Virol 89:4387–4404. doi:10.1128/JVI.02705-14.Abstract/
19.Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J. 2020. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395:e30–e31. doi:10.1016/S0140-6736(20)30304-4.
20.Blaising J, Polyak SJ, Pecheur EI. 2014. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 107:84–94. doi:10.1016/j.antiviral.2014.04.006.
21.Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271. doi:10.1038/s41422-020-0282-0.
22.Gao J, Tian Z, Yang X. 19 February 2020, posting date. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends doi:10.5582/bst.2020.01047.
23.Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. 9 March 2020, posting date. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis doi:10.1093/cid/ciaa237.
24.Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. 2003. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis 3:722–727. doi:10.1016/S1473-3099(03)00806-5.
25.Martinez MA. 9 March 2020, posting date. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother doi:10.1128/AAC.00399-20.
26.Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M. 24 February 2020, posting date. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem doi:10.1074/jbc.AC120.013056.
27.Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK, Washington State 2019-nCoV Case Investigation Team. 2020. First case of 2019 novel coronavirus in the United States. N Engl J Med 382:929–936. doi:10.1056/NEJMoa2001191.
28.Li G, De Clercq E. 2020. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov 19:149–150. doi:10.1038/d41573-020-00016-0.
29.Morse JS, Lalonde T, Xu S, Liu WR. 2020. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem 21:730–738. doi:10.1002/cbic.202000047.
30.Li YZJ, Wang N, Li H, Shi Y, Guo G, Liu K, Zeng H, Zou Q. 2020. Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening. BioRxiv https://www.biorxiv.org/content/10.1101/2020.01.28.922922v2.
31.Nguyen TM, Zhang Y, Pandolfi PP. 2020. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses. Cell Res 30:189–190. doi:10.1038/s41422-020-0290-0.
32.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. doi:10.1016/S0140-6736(20)30183-5.
33.Zhou YF, Zheng X, Wang D, Zhao C, Qi Y, Sun R, Tian Z, Xu X, Wei H. 2020. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. BioRxiv https://doi.org/10.1101/2020.02.12.945576.
34.Russell CD, Millar JE, Baillie JK. 2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395:473–475. doi:10.1016/S0140-6736(20)30317-2.
35.Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, Hu M, Fang M, Gao Y. 2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther 5:18. doi:10.1038/s41392-020-0127-9.
36.Fu Y, Cheng Y, Wu Y. 3 March 2020, posting date. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin doi:10.1007/s12250-020-00207-4.
37.Chen L, Xiong J, Bao L, Shi Y. 27 February 2020, posting date. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis doi:10.1016/S1473-3099(20)30141-9.
38.Garraud O, Heshmati F, Pozzetto B, Lefrere F, Girot R, Saillol A, Laperche S. 2016. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol 23:39–44. doi:10.1016/j.tracli.2015.12.003.
39.Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, Grazzini G. 2016. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus 14:152–157. doi:10.2450/2015.0131-15.
40.National Health Commission of the People’s Republic of China. 2020. Notice on printing and distributing the convalescent plasma treatment for novel coronavirus pneumonia (trial version 2). http://www.nhc.gov.cn/yzygj/s7658/202003/61d608a7e8bf49fca418a6074c2bf5a2.shtml. Accessed 4 March 2020.
41.Lu S. 2020. Timely development of vaccines against SARS-CoV-2. Emerg Microbes Infect 9:542–544. doi:10.1080/22221751.2020.1737580.
42.Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367:1260–1263. doi:10.1126/science.abb2507.Abstract/
43.Lucchese G. 24 February 2020, posting date. Epitopes for a 2019-nCoV vaccine. Cell Mol Immunol doi:10.1038/s41423-020-0377-z.
44.Ahmed SF, Quadeer AA, McKay MR. 2020. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12:E254. doi:10.3390/v12030254.
45.Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI, Gutierrez RA, Gwee SXW, Chua PEY, Yang Q, Ng XY, Yap RK, Tan HY, Teo YY, Tan CC, Cook AR, Yap JC, Hsu LY. 26 February 2020, posting date. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. J Clin Med doi:10.3390/jcm9030623.
46.CEPI. 2020. CEPI to fund three programmes to develop vaccines against the novel coronavirus, ncov-2019. https://cepi.net/news_cepi/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019/. Accessed on 29 January 2020.

More information: Mehdi Bouhaddou et al, The Global Phosphorylation Landscape of SARS-CoV-2 Infection, Cell (2020). DOI: 10.1016/j.cell.2020.06.034


Please enter your comment!
Please enter your name here

Questo sito usa Akismet per ridurre lo spam. Scopri come i tuoi dati vengono elaborati.